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Abstract
Objective This review aims at updating the results of
cardiac resynchronization therapy (CRT) in mild heart
failure patients, and investigating whether CRTcan prevent
or reverse heart failure progression in an earlier stage.
Methods Randomized controlled trials of CRTin patients with
New York Heart Association (NYHA) Class I or II heart failure
were identified. The effects of CRTon worsening heart failure
hospitalization, all-cause mortality, and overall adverse events
were meta-analyzed, and the effects of CRTon left ventricular
(LV) were systematically reviewed and meta-analyzed.
Results Eight studies were identified with a total of 4,302
patients. CRT was associated with a substantial improve-
ment in LVend-systolic volume (WMD −39, 95%CI −41.56
to −36.45). CRT also had a marked effect in reducing new
hospitalizations for worsening heart failure by 31% (RR 0.69,
95%CI 0.60 to 0.79). In addition, CRTsignificantly decreased
all-cause mortality by 21% (RR 0.79, 95%CI 0.67 to 0.93).
However, complications in patients with CRT increased by
74% (RR 1.74, 95%CI 1.44 to 2.11).
Conclusions This meta-analysis suggests that CRT could
improve the prognosis in patients with mild heart failure
and ventricular dyssynchrony, but these improvements are
accompanied by more adverse events. Since most patients
in the included trials had received ICD therapy, our analysis
suggests that CRTcould offer an additional benefit.
Key words Heart failure.Cardiac resynchronization
therapy.Meta-analysis
Introduction
Several large multi-center clinical trials have confirmed
that CRT not only can improve heart function, exercise
capacity and quality of life, but also reduce mortality and
hospitalization, and it can even improve the prognosis in
patients with moderate to severe heart failure (New York
Heart Association [NYHA] class III/IV) [1–6]. These
patients are characterized by severe heart failure symp-
toms, poor left ventricular (LV) systolic function (ejection
fraction [EF] ≤35%), and wide QRS (≥120 ms) on the
surface ECG as a sign of ventricular dyssynchrony.
However, for the advanced heart failure patients, especially
those with NYHA IV , the duration of these beneficial effects
affordedby CRTstill remains unknown.It appears that slowing
heart failure progression is the most important target. Subse-
quent trials, including the Multicenter Automatic Defibrillator
Implantation Trial With Cardiac Resynchronization (MADIT-
CRT) [7] and the extended follow-up of the Resynchroniza-
tion Reverses Remodeling in Systolic Left V entricular
Dysfunction (REVERSE) substudy of the European patient
cohort [8], were designed to test if CRT has clinical
advantages in patients with milder heart failure and the
results were encouraging. A meta-analysis of the MADIT -
CRT and REVERSE trials in patients with CRT and
implantable cardioverter–defibrillator (ICD) backup (CRT-D)
reported a significant reduction in a composite outcome of
heart failure events, but not mortality [9]. However, the recent
results of Resynchronization/Defibrillation for Ambulatory
Heart Failure Trial (RAFT) [10] showed the superiority of
CRT in reducing mortality and the combined outcome of
death from any cause or hospitalization related to heart
failure among patients receiving optimal medical therapy
and ICD.
The aim of this meta-analysis is to update the results
of CRT in mild heart failure in terms of reverse LV
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all-cause mortality by collecting all available data, as
well as the most recently published papers on CRT, and
further explore whether CRT could prevent or reverse
heart failure progression in patients with mild symptoms
(NYHA Class I/II).
Methods
Search strategy
Electronic searches of MEDLINE, EMBASE, CENTREN
and its affiliated clinical trial registration data center, US
Food and Drug Administration reports, Chinese Biomedical
Literature Database CD-ROM, VIP Chinese Science and
Technology Periodical Database, and China National
Knowledge Infrastructure databases from establishment to
Dec 2010, using the search terms “CRT, heart failure”,
“biventricular pacer, heart failure”, “biventricular pacing,
heart failure”,a n d“biventricular pacemaker, heart fail-
ure”, were performed to identify randomized controlled
trials (RCTs). Hand searches of bibliographies from
published meta-analyses and review articles and proceed-
ings booklets from conferences were also included to
ensure inclusion of all pertinent studies for the prelim-
inary review. In addition, we contacted authors of some
studies and device manufacturers for additional citations
and information. The searches were limited to studies
published in the English and Chinese language but not to
publication status.
Eligibility criteria
The types of participants considered were patients with
NYHA Class I/II symptoms, low EF (≤40%) and wide QRS
(≥120 ms). The NYHA Class was evaluated at baseline
before randomization. The technology being evaluated is
CRT, and the search strategy focused on RCTs in which an
experimental group included CRT vs the control group.
Studies were excluded if another report from the same trial
with more updated data was available. RCTs with a less
than 3 months follow-up or crossover trials with a less than
3 months follow-up during the first randomized crossover
phase were also excluded. To avoid a carry-over effect, only
the first randomized cross-over period was considered for
analysis.
Outcome assessment
We assessed reverse LV remodeling, hospitalization for
worsening heart failure, all-cause mortality, and overall
adverse events.
Data extraction and quality assessment
Two investigators (Zhong G, Tu R) independently extracted
data from each study. We used a standardized extraction
form to evaluate the study quality, including the study
design, length of follow-up and loss to follow-up, and
blinding of patients and investigators. Disagreements were
resolved by consensus with 5 other investigators (Zeng Z,
Wu W, Wu H, Cao X, Aung LHH). The data we collected
included clinical outcomes such as heart failure hospitali-
zation, death from any cause, and adverse events associated
with CRT, as well as basic data such as LV remodeling
parameters, median QRS duration and EF for each study.
Statistical analyses
The statistical analyses were performed using the RevMan
computer software (Cochrane Center: available at: http://
www.cochrane.org). Dichotomous outcomes were analyzed
by calculating the relative risk (RR) and continuous
outcomes were presented as a weighted mean difference
(WMD). A fixed effects model was used to pool data from
each trial. The 95% confidence intervals (CI) were used for
safety analysis. Statistical heterogeneity was quantified
using the chi-square test. When heterogeneity was present,
a random effects model was calculated.
Results
Search results
A total of 1,391 relevant references from all databases were
found (Fig. 1). Of these, full-text versions of 90 references
were retrieved for detailed evaluation. Only eight trials
fulfilled the inclusion criteria and were included in our
meta-analysis. These were the Safety and Effectiveness of
Cardiac Resynchronization Therapy With Defibrillation
(CONTAK CD) [11], Multicenter InSync Implantable
90 references full text
8 references
1301 excluded   
439 duplicates 
  354 basic research 
 508  non-RCT
Screening of title/abstract 
Detailed review of full text
1391 relevant references
82 excluded
Fig. 1 Study flow
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tion (MIRACLE ICD II) [12], the extension phase of
Cardiac Resynchronization–Heart Failure (CARE-HF
extension) [5, 13], MADIT-CRT [7], REVERSE Europe
[8], RAFT [10], Evaluation of Resynchronization Therapy
For Heart Failure In Patients With A QRS Duration Greater
Than 120 ms (Greater EARTH) [14] and van Geldorp et al.
[15] trials.
Study and patient characteristics
A total of 4,302 mild heart failure patients with median
LVEF ranging from 21.5% to 28% and median QRS
ranging from 155 to 195 ms were included. The baseline
patient characteristics and design of the trials were
described in Tables 1 and 2. 2 trials (298 patients) were
restricted to patients with LVEF less than 40% [8, 15], 4
trials (972 patients) less than 35% [5, 11, 12, 14], and 2
trials (3,618 patients) less than 30% [7, 10]. 3 trials (2,268
patients) enrolled patients with NYHA class I/II symptoms
exclusively [7, 8, 12], and in the other 5 trials, 21.5%–80%
of patients had NYHA class I/II symptoms. The median age
of the populations ranged between 61 and 66 years. The
median follow-up ranged between 6 months and
40 months.
The majority of subjects in each trial were male and
ischemic cardiomyopathy was the main etiology in five
trials [7, 10–12, 14]. Most trials excluded patients with
atrial fibrillation, and one trial evaluated the effects of CRT
in this population [10]. 94% of the control and 97.3% of the
CRT patients in the trials received an ICD and the use of
medical therapy like ACE inhibitors, angiotensin-receptor
blockers, and diuretics was comparably high. In contrast,
beta-blockers treatment ranged from 47% in CONTAK CD
to 93.4% in REVERSE Europe. In five trials, all patients
received CRT devices and were randomized in a parallel
way [8, 11, 12] or crossover design [14, 15] to CRT on or
off. In the three largest trials [5, 7, 10], patients were
randomized with or without receiving a CRT device.
Reverse left ventricular remodeling
Five trials [7, 8, 11, 12, 15] assessed the effect of CRT on
LV remodeling by comparing baseline and endpoint
echocardiographic parameters. CRT had been shown to
improve LV remodeling parameters of heart failure in each
study (Table 3). When limited to 6 months follow-up,
CONTAK CD [11], MIRACLE ICD II [12]a n dv a n
Geldorp et al. [15] showed a positive effect on LV structure
and function with CRT in NYHA Class I/II patients. In the
CONTAK CD [11], CRT demonstrated significant reduc-
tions in LV internal diameter in diastole and systole
(−2.4±0.8 vs. 0.0±0.8 mm, P=0.024 and −3.2±0.8
vs. −0.5±0.8 mm, P=0.014, respectively). In the MIRA-
CLE ICD II [12], CRT patients showed a significant
reduction in LV end-diastolic and end-systolic volumes
(−41±76 vs. −16±62 ml, P=0.04 and −42±77 vs. −14±
57 ml, P=0.01, respectively) and a significant increase in
LVEF (3.8±8.0% vs. 0.8±6.2%, P=0.02). A similar
improvement in LVEF (12±11% vs .5±11%), in association
with LVend-diastolic and end-systolic diameters (−4±7 vs.
−1±7 mm and −5±8 vs. −2±8 mm, respectively) and
volumes (−39±70 vs. −13±57 ml and −41±61 vs. −15±
55 ml, respectively) was reported with CRTin van Geldorp et
al. [15]. At 12 months of follow-up, MADIT-CRT [7]
revealed a significant improvement in LV end-systolic
volume index (L VESVi) (−26.2±16.5 vs. −7.4±7.2 mL/m
2,
P=0.0001) and L Vend—diastolic volume index (LVEDVi)
(−28.7±15.5 vs. −9.1±8.2 mL/m
2, P=0.0001) in association
with LVEF (11±5% vs. 3±3%, P=0.0001) with CRT. L V
diameters, L Vend-diastolic volume, LVend-systolic volume
(L VESV), and left atrial volume were also significantly
reduced to a greater extent in the CRT group in this trial. After
24 months follow-up, REVERSE Europe [8]d e m o n s t r a t e d
that LVESVi decreased by a mean of 27.5±31.8 mL/m
2 in
the CRT-ON group compared with 2.7±25.8 mL/m
2 in the
CRT-OFF group (P<0.0001). LVEDVi and LVEF had
similarly greater changes in the CRT ON than in the CRT
OFF group.
As the most obvious parameter of reverse remodeling,
LVESV was included in this meta-analysis to assess the
effects of CRTon reverse left ventricular remodeling. Three
trials [7, 12, 15] were included into a meta-analysis
showing that CRT had a marked effect on improvement in
LVESV (WMD −39, 95%CI −41.56 to −36.45; Fig. 2). No
statistical heterogeneity was found among the trials
(I
2=0%, P=0.51).
Heart failure hospitalization
Six trials [7, 8, 10–12, 14] provided data on patients
experiencing heart failure related hospitalization. Four
studies showed an absolute reduction in heart failure
hospitalization in patients treated with CRT. When pooling
the data together (4,039 patients), a significant relative
reduction of 31% in this endpoint was observed among
patients treated with CRT (RR 0.69, 95%CI 0.60 to 0.79,
Fig. 3). No evidence of statistical heterogeneity was
observed between trials regarding this effect (I
2=29%,
P=0.21).
All-cause mortality
Data on the all-cause mortality was obtained for each trial.
Only the RAFT trial [10] reported a statistically significant
reduction in all-cause mortality in patients with CRT as
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334 Cardiovasc Drugs Ther (2011) 25:331–340compared to the control group (RR 0.74, 95%CI 0.59 to 0.92).
When pooling data from all studies together (4,302 patients),
we found that CRTsignificantly reduced all-cause mortality by
21% (RR 0.79, 95%CI 0.67 to 0.93) compared to the control
group (Fig.4). No heterogeneity was observed among RRs for
all-cause mortality reported in the studies (I
2=0%, P=0.68).
Complications
Four trials [7, 8, 10, 12] mentioned complications or adverse
events for device implantation. In two of these, both CRT
groups [8, 12] reported the percentage of patients with
complications, consisting mainly of lead dislodgements
which occurred 8.5% during peri—implantation and 5.9%
after implantation. Only one trial [8] provided complications
separately, and no significant difference was found between
the two groups (RR 1.04, 95%CI 0.45 to 2.43). The other
two largest trials [7, 10] reported that adverse events within
30 days after device implantation was significantly higher
among patients in the CRT-D group than among those in the
ICD-only group (RR 1.79, 95%CI 1.47 to 2.18). In Fig. 5
the forest plot indicates that the complications in patients
with CRT increased by 74% compared with the control
group (RR 1.74, 95%CI 1.44 to 2.11) after pooling the data
from three trials [7, 8, 10]. No evidence of statistical
heterogeneity was reported (I
2=6%, P=0.35).
Discussion
Over 4,000 patients were evaluated in this meta-analysis on
CRT in mild heart failure patients with left ventricular
systolic dysfunction and broad QRS complex. The results
showed that CRT improved LVESV (P<0.00001), reduced
new hospitalizations for worsening heart failure by 31%
(P<0.00001) and all-cause mortality by 21% (P=0.006).
Compared with the published meta-analyses [16, 17],
firstly, the present study included more trials, which
demonstrates the convincing effect of CRT on mortality
and morbidity in mild heart failure patients. Secondly, the
result of our meta-analysis show that the complications in
patients with CRT increased by 74%(P<0.00001). Given
the fact that the follow-up period might be an important
factor to detect an improvement in patients with mild heart
failure, another noted difference is that we used the
extended follow-up of the REVERSE trial [18]: 24-month
clinical and left ventricular remodeling outcomes which
were reported by the European cohort.
In the current study, we found that CRT could improve
LVESV in patients with NYHA I/II symptoms, which is
consistent with the other studies [19, 20]. These improve-
ments were accompanied by a significant delay in time to
first heart failure hospitalization or death, indicating that
reverse remodeling by CRTwas linked to reduced morbidity
and mortality [7, 8, 21]. It is worth mentioning that MADIT-
CRT [7] also showed a significant reduction in left atrial
volume. Most likely, this reduction will lead to a lower
incidence of new-onset atrial fibrillation. Reducing the
occurrence of atrial fibrillation will further help prevent
progression of heart failure [22]. Therefore, our analyses
suggest that CRTwas associated with a long-term beneficial
effect on disease progression in mild heart failure patients.
An important finding in our analyses was the significant
decrease in all-cause mortality seen after CRT. CRT has
previously been demonstrated to reduce all-cause mortality
in patients with NYHA class III and IV symptoms [4, 5].
Only recently the RAFT trial [10] demonstrated a signifi-
cant reduction in overall mortality in NYHA class I/II
patients with CRT. Prior to RAFT, CARE HF, in which 175
patients who reported themselves to be in NYHA class I/II,
but were assessed as NYHA class III/IV ,a l s ob e n e f i t t e df r o m
CRT with respect to the combined outcome of all-cause
mortality or hospitalization for heart failure [13], and so did
the Comparison of Medical therapy, Pacing and Defibrilla-
tion in Heart Failure study (COMPANION) [4].
Early studies such as CONTAK CD and MIRACLE ICD
II also measured symptoms like NYHA class, which did not
change significantly after 6 months of CRT compared with
the control treatment. This was not unexpected, given the
fact that patients with NYHA class I/II heart failure had a
smaller symptom burden and the observation time for such
improvements needs to be longer than 6 months. As
objective assessments of circulatory capacity and respiratory
response to exercise, peak oxygen consumption(peak VO2)
and minute ventilation/minute carbon dioxide production
Table 2 Patient features between control arm and CRTarm
Control CRT
Patients, n 1937 2453
Age, y 64.4 63.7
Men,% 79.2 79.0
Ischaemic,% 55.3 54.5
Atrial fibrillation or flutter,% 5.8 4.4
LVEF,% 23.9 24.3
QRS, ms 182.8 166.8
ACEI or ARB,% 95.9 95.4
β-blockers,% 79.3 81.0
Diuretic,% 80.6 83.4
NYHA II,% 74.6 74.3
ICD,% 94.0 97.3
LVEF left ventricular ejection fraction; ACEI angiotensin-converting
enzyme inhibitor; ARB angiotensin receptor blocker; NYHA New Y ork
Heart Association; ICD implantable cardioverter–defibrillator; CRT
cardiac resynchronization therapy
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336 Cardiovasc Drugs Ther (2011) 25:331–340(VE/VCO2) are important cardiopulmonary exercise test
parameters and known powerful predictor of prognosis [23,
24], these parameters have been used qualifying patients for
implantation and evaluating the results of therapy in many
studies with CRT [12, 25–27]. However, VE/VCO2, but not
peak VO2 was improved by CRT in NYHA I/II heart failure
patients [11, 12]. It is difficult to explain this difference, as
only one trial [12] measured both parameters in this
population.
As 94% in the control and 97.3% in the CRT had an ICD
in our meta-analyses, the benefits of CRT in our study
represent additional benefits to those expected from the
ICD alone. Further, there is some current evidence
supporting the use of CRT-D in these populations. However,
CRT-D seemed to be associated with a higher risk of device-
related complications such as LV lead repositioning,
infection incidences, pneumothorax, pocket hematomas
requiring evacuation, and coronary venous dissection as
compared with ICD [28–30]. Although many of these
adverse events did not have substantial long-term conse-
quences, they may have caused substantial morbidity and
increased the overall cost to health care systems. Since the
economic feasibility of CRT implantation in patients with
mild heart failure remains uncertain [31], it is of utmost
importance to assess how patients can maximally benefit
from CRT. Nowadays, structured exercise training has been
widely accepted in patients with CRT to further improve the
functional status, and to ensure the best possible outcome
from CRT [32].
It is noteworthy that patients with less severe LV
dysfunction (LVEF >35% or more) appear to acquire
significant clinical and structural benefit from CRT [14,
33]. Currently, up to 22% of patients receiving CRT have
NYHA Class I or II symptoms and up to 17% have a LVEF
above 35% [34]. The European Society of Cardiology has
extended its recommendation for CRT to patients with
NYHA class II symptoms, LVEF of 35% or less, wide QRS
duration of 150 ms or more, and sinus rhythm [35].
Moreover, it is expected that it might even be extended to
diastolic heart failure with a preserved EF in future
studies [36].
Limitations of the study
A number of limitations of the present analysis should be
noted. Firstly, though the specific cause of death was
reported in two studies [8, 10], only one of them[10]
reported this separately, so we can only access all-cause
mortality. Secondly, the data of echocardiographic parameters
werepartiallyreportedinmosttrialsandwerenotconsistently
Fig. 3 Forest plot demonstrated the effects of CRT on heart failure hospitalization, risk ratio and 95% confidence intervals. Outcomes were
pooled using fixed-effects modeling
Fig. 2 Forest plot demonstrated the effects of CRT on LVESV , mean difference and 95% confidence intervals. Outcomes were pooled using
fixed-effects modeling
Cardiovasc Drugs Ther (2011) 25:331–340 337provided in a poolable format (Table 3). As a result, we
evaluated the effects of CRTon left ventricular remodeling
by systematical review and meta-analysis of LVESV .
Thirdly, NYHA class is in fact not a fixed or highly
reproducible measurement, which will fluctuate over time
in response to changes in organ function, mood, expect-
ations, and exercise training [32] in individual patients. To
some extent, it may not be appropriate to select patients
for CRT on the basis of severity of their symptoms in the
presence of LV dysfunction and markers of dyssynchrony
[13]. After all, the objective of treatment is to improve
long-term prognosis. Finally, this meta-analysis included
only 8 RCTs and one of them was a retrospectively
defined analysis [13]. More randomized trials with a
longer follow-up are needed to better evaluate the effect
of CRT in mild heart failure patients.
Conclusion
In summary, our analysis shows that standard pharmacolog-
ically managed mild heart failure patients with ventricular
dyssynchrony substantially benefit from CRT in terms of
reverse LVremodeling and reducing heart failure hospitaliza-
Fig. 4 Forest plot demonstrated the effects of CRTon all-cause mortality, risk ratio and 95% confidence intervals. Outcomes were pooled using
fixed-effects modeling
Fig. 5 Forest plot demonstrated the complications with CRT, risk ratio and 95% confidence intervals. Outcomes were pooled using
fixed-effects modeling
338 Cardiovasc Drugs Ther (2011) 25:331–340tion and all-cause mortality. Since most patients in the
included trials received ICD therapy, our analysis suggests
that CRT may offer a benefit additional to that of ICD. This
meta-analysis also indicates that prevention of disease
progression could be well accomplished by CRTin mild heart
failurepatients.However,thesebenefitswereaccompaniedby
more adverse events.
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